Chronic urticaria has strong autoimmune roots in a large proportion of cases. Up to 50% of people with chronic spontaneous urticaria (CSU) have an identifiable autoimmune mechanism driving their hives, where the immune system produces antibodies that mistakenly activate the skin’s own mast cells. The other half of cases involve non-immune triggers or mechanisms that aren’t yet fully understood. So the short answer is: it’s not always autoimmune, but it very often is.
Two Autoimmune Subtypes of Chronic Urticaria
Researchers now recognize two distinct autoimmune pathways behind CSU, and the distinction matters because they work differently at the cellular level.
The first is called Type I autoallergic CSU. In this form, your body produces IgE antibodies that react against your own proteins instead of against outside invaders like pollen or dust mites. These self-targeting IgE antibodies latch onto mast cells in the skin and trigger them to release histamine, just as they would during an allergic reaction. The difference is there’s no external allergen involved. One protein called IL-24 has been identified as a particularly common target: IgE antibodies against IL-24 were found in 80% of CSU patients in one study, compared to only 20% of healthy controls. Higher levels of these antibodies correlated with more active disease and lower basophil counts in the blood.
The second form is Type IIb autoimmune CSU, which works through a different class of antibodies called IgG. These autoantibodies directly attack the IgE receptor on mast cells or target IgE molecules themselves. When these autoantibodies bind to the receptor, mast cells release histamine without any allergen being present. This type tends to be associated with more severe symptoms. Recent research also suggests IgM antibodies against the same receptor may be even more common than IgG in some patients, adding another layer to the picture.
How Autoimmune CSU Is Diagnosed
Identifying whether your chronic hives have an autoimmune basis involves a combination of tests rather than a single blood draw. The most established approach, outlined in the PURIST study criteria, requires three things to confirm Type IIb autoimmune CSU: a positive autologous serum skin test (where a small amount of your own blood serum is injected into your skin to see if it triggers a wheal), a blood test detecting IgG autoantibodies against the IgE receptor, and a positive basophil reactivity test showing that your serum can activate immune cells in a lab setting.
The autologous serum skin test is considered positive when the resulting wheal is more than 1.5 mm larger than a saline control injection at 30 minutes. For the basophil activation test, labs look for a surface marker called CD63 on basophils. Resting basophils don’t express this marker, but activated ones do. A result is positive when more than 5% of basophils show CD63 and the activation is at least double the baseline level. These tests aren’t widely available at every clinic, which is one reason the autoimmune subtype often goes unrecognized.
The Thyroid Connection
One of the strongest clues that autoimmunity plays a role in CSU is its overlap with autoimmune thyroid disease. Depending on the study, anywhere from 4.3% to 57.4% of adults with CSU also have an autoimmune thyroid condition like Hashimoto’s thyroiditis or Graves’ disease. That’s a remarkably wide range, but even the low end is well above what you’d expect by chance. The association is strongest in adult women.
Beyond thyroid disease, people with CSU have higher rates of several other autoimmune conditions, though each individual one is less common. About 1% of CSU patients also have type 1 diabetes, rheumatoid arthritis, celiac disease, vitiligo, or autoimmune hemolytic anemia. Broader studies have also found links to lupus, psoriasis, Sjögren’s syndrome, and inflammatory bowel disease. These overlapping conditions share genetic components and immune pathways, reinforcing the idea that CSU sits within a broader autoimmune landscape for many patients.
This is why thyroid antibody testing (anti-thyroglobulin and anti-thyroid peroxidase) is part of the routine workup for CSU patients in many clinics, even when thyroid function seems normal.
How Mast Cells Get Caught in the Crossfire
Regardless of the specific autoimmune subtype, the end result is the same: mast cells in the skin get activated when they shouldn’t be. In healthy skin, mast cells sit quietly until a genuine threat arrives. In autoimmune CSU, your own antibodies are constantly prodding these cells to release histamine and other inflammatory chemicals.
The process can also recruit other immune cells into the cycle. Eosinophils, a type of white blood cell normally involved in fighting parasites, get activated and release granule proteins that further stimulate mast cells. This creates a self-sustaining loop of inflammation. Some autoantibodies also trigger eosinophils through a low-affinity IgE receptor on their surface, which in turn causes additional histamine release from basophils. This interaction between mast cells, basophils, and eosinophils helps explain why chronic urticaria can be so persistent and difficult to control with antihistamines alone.
Treatment Response Across Subtypes
One practical question that follows from the autoimmune classification is whether it changes how well treatments work. The biologic therapy omalizumab, which targets IgE, is effective across both autoimmune and non-autoimmune CSU. Research published in Scientific Reports found that patients with autoantibodies and those without responded equally well in the long run. There was one notable difference in timing: patients with a positive autologous serum skin test tended to respond faster to omalizumab, but final outcomes were the same regardless of autoimmune status.
This is somewhat surprising because omalizumab was designed to block free IgE, and its effectiveness in Type IIb cases (where IgG autoantibodies are the main driver, not IgE) suggests the drug works through additional mechanisms that aren’t fully mapped out yet. For patients, the practical takeaway is reassuring: having the autoimmune subtype doesn’t mean you’re less likely to respond to available treatments.
Not Purely Autoimmune, Not Purely Allergic
The international urticaria guideline from EAACI, GA²LEN, and partner organizations defines CSU as a “mast cell-driven disease,” which is deliberately broader than calling it autoimmune. This reflects the reality that while autoimmunity accounts for a large share of cases, other factors including complement system activation, neuropeptides, and host defense peptides can also trigger mast cells independently of autoantibodies.
The current thinking treats CSU as a spectrum. On one end are clearly autoimmune cases with detectable autoantibodies and overlapping autoimmune conditions. On the other are cases where no autoimmune markers can be found, sometimes called “idiopathic” simply because the trigger remains unknown. Many patients fall somewhere in between, with some markers of autoimmunity but not enough to meet full diagnostic criteria. Researchers have proposed that some of these in-between cases may involve autoinflammatory mechanisms, where the innate immune system overreacts without the specific antibody-targeting seen in classic autoimmune disease.
For the roughly half of CSU patients whose disease is autoimmune, this classification has real implications. It means screening for associated conditions like thyroid disease is worthwhile, it helps explain why standard antihistamines often fall short, and it opens the door to immune-modulating therapies that address the underlying cause rather than just suppressing symptoms.